Why Invest In Aterovax?

Atherosclerosis is the major underlying cause of CVD, which represents a large commercial market. Thanks to its thorough understanding of the inflammatory processes in the context of atherosclerosis, Aterovax has been able to develop and validate in a very short time a potent biomarker of the vulnerable or destabilized plaque. Clinical data has demonstrated that Aterovax’s sPLA2 activity test is a powerful tool for detecting the presence of a destabilized plaque, and hence both a predictor of risk for coronary heart disease in the asymptomatic population (primary prevention), as well as a predictor of cardiac events in patients with coronary syndromes (secondary prevention).

This unique test will guide physicians to the presence of a vulnerable plaque independently, over and above traditional risk markers (cholesterol), risk scores (Framingham Risk Score) and well-established risk markers such as hs-CRP.

Aterovax will generate revenue by commercializing its innovative sPLA2 Activity Test through reference labs. Following regulatory approvals in Europe and the US, sales could significantly increase by addressing the primary and secondary prevention markets through partnerships with in vitro diagnostics companies.